News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management


25 June 2008 CSL Behring Awards LEAD Grants to Support Patient Group Advocacy Efforts

CSL Behring announced it has recently awarded seven grants totaling more than $90,000 to patient advocacy organizations in the United States. The seven grants represent the first round of awards in the company's Local Empowerment for Advocacy Development (LEAD) program. CSL Behring is a global leader in the plasma protein biotherapeutics industry. LEAD grants support grassroots advocacy efforts by organizations committed to helping people with rare diseases who use plasma-derived and recombinant therapies to manage their health conditions. CSL Behring awards LEAD grants semiannually.

> Read More
01 April 2008 CSL Behring Signs Agreements with Canadian Blood Services and Héma-Québec to Supply Life-Saving Therapies

CSL Behring Canada, Inc. today announced that Canadian Blood Services, and Héma-Québec, have each awarded the company contracts to supply Helixate® FS ( Antihemophilic Factor [Recombinant]), Humate® P (Antihemophilic factor / von Willebrand Factor Complex [Human], Dried, Pasteurized), Privigen (Immune Globulin Intravenous [Human]), Vivaglobin® (Immune Globulin Subcutaneous [Human]) and other plasma-derived products. These products are used for the treatment of conditions such as hemophilia, von Willebrand Disease, primary immunodeficiency as well as other serious conditions.

> Read More
20 February 2008 CSL Behring Launches LEAD Program to Support Patient Group Advocacy Efforts

CSL Behring, a global leader in the plasma protein biotherapeutics industry, is launching a new program to support patient organizations’ grassroots advocacy efforts in the United States. Called Local Empowerment for Advocacy Development, or LEAD, the program will make grants available to groups of patients who have rare diseases and who use plasma-derived and recombinant therapies to manage their conditions. The program, which is the latest initiative in CSL Behring’s continued commitment to patient advocacy, includes two initiatives: LEAD Grants and Raise Your Voice!, a youth-focused advocacy training program.

> Read More
10 December 2007 Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)

CSL Limited, Australia’s leading biopharmaceutical company, has today presented data at the American Society of Hematology (ASH) 49th annual meeting, which demonstrate the promising pre-clinical activity of a novel monoclonal antibody, in the potential treatment of acute myeloid leukemia (AML).

> Read More
Page 6 of 6 First | Previous

LinkedIn Twitter Facebook Google+